No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19
The relation between pre-vaccination antipyretic use and antibody responses to SARS-CoV-2 vaccination has been unclear. We measured the pre- and post-BNT162b2 booster spike-specific IgG titers and recorded antipyretic use and adverse reactions for SARS-CoV-2-naive hospital healthcare workers. The da...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136222000845 |
| _version_ | 1797978157569015808 |
|---|---|
| author | Naoki Tani Hideyuki Ikematsu Takeyuki Goto Kei Gondo Yuki Yanagihara Yasuo Kurata Ryo Oishi Junya Minami Kyoko Onozawa Sukehisa Nagano Hiroyuki Kuwano Koichi Akashi Nobuyuki Shimono Yong Chong |
| author_facet | Naoki Tani Hideyuki Ikematsu Takeyuki Goto Kei Gondo Yuki Yanagihara Yasuo Kurata Ryo Oishi Junya Minami Kyoko Onozawa Sukehisa Nagano Hiroyuki Kuwano Koichi Akashi Nobuyuki Shimono Yong Chong |
| author_sort | Naoki Tani |
| collection | DOAJ |
| description | The relation between pre-vaccination antipyretic use and antibody responses to SARS-CoV-2 vaccination has been unclear. We measured the pre- and post-BNT162b2 booster spike-specific IgG titers and recorded antipyretic use and adverse reactions for SARS-CoV-2-naive hospital healthcare workers. The data of 20 cases who used antipyretics within 24 h before vaccination were compared to that of 281 controls. The post-booster geometric mean IgG titers were 15,559 AU/mL (95 % CI, 11,474–21,203) for the cases and 16,850 AU/mL (95 % CI, 15,563–18,243) for the controls (p = 0.622). No significant reduction in the frequency or severity of any of the solicited adverse reactions was found for the cases. Similar results were obtained after adjustment with propensity-score matching for demographic characteristics, baseline IgG titer, and post-vaccination antipyretic use. Antipyretic use within 24 h before vaccination would not affect mRNA COVID-19 vaccine-induced specific antibody responses and that postponement of vaccination due to pre-vaccination antipyretic use would be unnecessary. |
| first_indexed | 2024-04-11T05:18:29Z |
| format | Article |
| id | doaj.art-7d5f1578696f47d39ca69946bf76a72f |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-04-11T05:18:29Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-7d5f1578696f47d39ca69946bf76a72f2022-12-24T04:57:11ZengElsevierVaccine: X2590-13622022-12-0112100224No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19Naoki Tani0Hideyuki Ikematsu1Takeyuki Goto2Kei Gondo3Yuki Yanagihara4Yasuo Kurata5Ryo Oishi6Junya Minami7Kyoko Onozawa8Sukehisa Nagano9Hiroyuki Kuwano10Koichi Akashi11Nobuyuki Shimono12Yong Chong13Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanRicerca Clinica Co., Fukuoka, JapanMedicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanClinical Laboratory, Fukuoka City Hospital, Fukuoka, JapanPharmacy, Fukuoka City Hospital, Fukuoka, JapanPharmacy, Fukuoka City Hospital, Fukuoka, JapanDepartment of Infectious Diseases, Fukuoka City Hospital, Fukuoka, JapanDepartment of Infectious Diseases, Fukuoka City Hospital, Fukuoka, JapanDepartment of Infectious Diseases, Fukuoka City Hospital, Fukuoka, JapanDepartment of Neurology, Fukuoka City Hospital, Fukuoka, JapanFukuoka City Hospital, Fukuoka, JapanMedicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanCenter for the Study of Global Infection, Kyushu University Hospital, Fukuoka, JapanMedicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Corresponding author at: Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ward, Fukuoka 812-8582, Japan.The relation between pre-vaccination antipyretic use and antibody responses to SARS-CoV-2 vaccination has been unclear. We measured the pre- and post-BNT162b2 booster spike-specific IgG titers and recorded antipyretic use and adverse reactions for SARS-CoV-2-naive hospital healthcare workers. The data of 20 cases who used antipyretics within 24 h before vaccination were compared to that of 281 controls. The post-booster geometric mean IgG titers were 15,559 AU/mL (95 % CI, 11,474–21,203) for the cases and 16,850 AU/mL (95 % CI, 15,563–18,243) for the controls (p = 0.622). No significant reduction in the frequency or severity of any of the solicited adverse reactions was found for the cases. Similar results were obtained after adjustment with propensity-score matching for demographic characteristics, baseline IgG titer, and post-vaccination antipyretic use. Antipyretic use within 24 h before vaccination would not affect mRNA COVID-19 vaccine-induced specific antibody responses and that postponement of vaccination due to pre-vaccination antipyretic use would be unnecessary.http://www.sciencedirect.com/science/article/pii/S2590136222000845AntipyreticSARS-CoV-2VaccineAntibodyReactogenicityBooster |
| spellingShingle | Naoki Tani Hideyuki Ikematsu Takeyuki Goto Kei Gondo Yuki Yanagihara Yasuo Kurata Ryo Oishi Junya Minami Kyoko Onozawa Sukehisa Nagano Hiroyuki Kuwano Koichi Akashi Nobuyuki Shimono Yong Chong No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 Vaccine: X Antipyretic SARS-CoV-2 Vaccine Antibody Reactogenicity Booster |
| title | No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 |
| title_full | No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 |
| title_fullStr | No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 |
| title_full_unstemmed | No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 |
| title_short | No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 |
| title_sort | no significant influence of pre vaccination antipyretic use on specific antibody response to a bnt162b2 vaccine booster against covid 19 |
| topic | Antipyretic SARS-CoV-2 Vaccine Antibody Reactogenicity Booster |
| url | http://www.sciencedirect.com/science/article/pii/S2590136222000845 |
| work_keys_str_mv | AT naokitani nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT hideyukiikematsu nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT takeyukigoto nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT keigondo nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT yukiyanagihara nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT yasuokurata nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT ryooishi nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT junyaminami nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT kyokoonozawa nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT sukehisanagano nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT hiroyukikuwano nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT koichiakashi nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT nobuyukishimono nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 AT yongchong nosignificantinfluenceofprevaccinationantipyreticuseonspecificantibodyresponsetoabnt162b2vaccineboosteragainstcovid19 |